V
Viome
Provides the industry’s only direct-to-consumer healthcare test that analyzes microbial and human gene expressions (mRNA)
About Viome
Viome operates in the health and wellness market, focusing on personalized nutrition and gut health solutions. The company serves individuals seeking to optimize their health through tailored dietary and supplement recommendations. Viome's core business model revolves around offering health tests that analyze the microbiome and cellular health, providing personalized insights and nutrition plans based on the results. The company leverages advanced mRNA technology and artificial intelligence to deliver precise health recommendations. Revenue is generated through the sale of health tests, personalized supplements, and probiotics subscriptions. Viome's target market includes health-conscious consumers looking for data-driven, personalized health solutions.
Source: Dealroom company dataAt a glance
- Founded
- 2016
- Headquarters
- Bellevue, United States
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Bold Capital Partners
Khosla Ventures- PPPhysician Partners
Marc Benioff
Ezaki Glico
WestRiver Group- OCOcgrow Group of Companies
Series B and later1 investor entered at this stage
Bold Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Viome on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Viome on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.